破解肺癌靶向耐药困境，上海专家团队临床研究登上《柳叶刀》

Core Insights - A significant breakthrough in treating advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations and MET amplification has been achieved through a "dual-target" therapy combining Savolitinib and Osimertinib, offering new treatment options for patients facing resistance to targeted therapies [3][5]. Group 1: Research Findings - In China, 40%-50% of lung adenocarcinoma patients exhibit EGFR gene mutations, with MET amplification being a major cause of resistance to EGFR-targeted therapies [2][3]. - The study led by Professor Lu Shun involved 211 patients who were randomly assigned to receive either the combination therapy or standard chemotherapy, revealing a median progression-free survival of 8.2 months for the combination group compared to 4.5 months for the chemotherapy group [4]. - The risk of disease recurrence or death was reduced by 66% in the combination therapy group, with 58% of patients achieving objective response compared to 34% in the chemotherapy group [4]. Group 2: Regulatory and Clinical Impact - The combination therapy of Savolitinib and Osimertinib has received approval from the National Medical Products Administration of China for treating EGFR mutation-positive patients with advanced or metastatic non-squamous NSCLC after progression on EGFR-TKI therapy [5]. - Professor Lu Shun has led 29 domestic and international studies on lung cancer, including 17 national Class 1 new drug studies, contributing to the approval and inclusion of several innovative drugs in medical insurance [6].